본문 바로가기
KERD
논문KCI 등재

Clinical implications of the Hippo-YAP pathway in multiple cancer contexts

김한별|명승재
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2018.03|BMB Reports|제51권 제3호|pp. 119-125

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

CancerTumorYAPDrug-resistantHippo pathway
주제분류화학

초록

The Hippo pathway plays prominent and widespread roles in various forms of human carcinogenesis. Specifically, the Yes-associated protein (YAP), a downstream effector of the Hippo pathway, can lead to excessive cell proliferation and the inhibition of apoptosis, resulting in tumorigenesis. It was reported that the YAP is strongly elevated in multiple types of human malignancies such as breast, lung, small intestine, colon, and liver cancers. Recent work indicates that, surprisingly, Hippo signaling components’ (SAV1, MST1/2, Lats1/2) mutations are virtually absent in human cancer, rendering this signaling an unlikely candidate to explain the vigorous activation of the YAP in most, if not all human tumors and an activated YAP promotes the resistance to RAF-, MAPK/ERK Kinase (MEK)-, and Epidermal growth factor receptor (EGFR)-targeted inhibitor therapy. The analysis of YAP expressions can facilitate the identification of patients who respond better to an anti-cancer drug treatment comprising RAF-, MEK-, and EGFR-targeted inhibitors. The prominence of YAP for those aspects of cancer biology denotes that these factors are ideal targets for the development of anti-cancer medications. Therefore, our report strongly indicates that the YAP is of potential prognostic utility and druggability in various human cancers.

Abstract

The Hippo pathway plays prominent and widespread roles in various forms of human carcinogenesis. Specifically, the Yes-associated protein (YAP), a downstream effector of the Hippo pathway, can lead to excessive cell proliferation and the inhibition of apoptosis, resulting in tumorigenesis. It was reported that the YAP is strongly elevated in multiple types of human malignancies such as breast, lung, small intestine, colon, and liver cancers. Recent work indicates that, surprisingly, Hippo signaling components’ (SAV1, MST1/2, Lats1/2) mutations are virtually absent in human cancer, rendering this signaling an unlikely candidate to explain the vigorous activation of the YAP in most, if not all human tumors and an activated YAP promotes the resistance to RAF-, MAPK/ERK Kinase (MEK)-, and Epidermal growth factor receptor (EGFR)-targeted inhibitor therapy. The analysis of YAP expressions can facilitate the identification of patients who respond better to an anti-cancer drug treatment comprising RAF-, MEK-, and EGFR-targeted inhibitors. The prominence of YAP for those aspects of cancer biology denotes that these factors are ideal targets for the development of anti-cancer medications. Therefore, our report strongly indicates that the YAP is of potential prognostic utility and druggability in various human cancers.

참고문헌 (94)

  1. Harvey K, "The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network", Nat Rev Cancer, 7, pp.182~191 (2007)[DOI]
  2. Meignin C, "The salvador-warts-hippo pathway is required for epithelial proliferation and axis specification in Drosophila", Curr Biol, 17, pp.1871~1878 (2007)[DOI]
  3. Zhang X, "Transcriptional output of the Salvador", warts, Cancer Res, pp.2009, 69[DOI]
  4. Huang J, "The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP", Cell, 122, pp.421~434 (2005)[DOI]
  5. Kango-Singh M, "Singh, Regulation of organ size: insights from the Drosophila Hippo signaling pathway", Dev Dyn, 238, pp.1627~1637 (2009)[DOI]
  6. Pan D, "Hippo signaling in organ size control", Genes Dev, 21, pp.886~897 (2007)[DOI]
  7. Zhang L, "Hippo signaling pathway and organ size control", Fly (Austin), 3, pp.68~73 (2009)[DOI]
  8. Wang K, "YAP, TAZ, and Yorkie: a conserved family of signal-responsive transcriptional coregulators in animal development and human disease", Biochem Cell Biol, 87, pp.77~91 (2009)[DOI]
  9. Xu T, "Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase", Development, 121, pp.1053~1063 (1995)
  10. Pantalacci S, "The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila", Nat Cell Biol, 5, pp.921~927 (2003)[DOI]
  11. Jia J, "The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis", Genes Dev, 17, pp.2514~2519 (2003)[DOI]
  12. Udan RS, "Hippo promotes proliferation arrest and apoptosis in the Salvador", Warts pathway, 2003, pp.5, 914~920
  13. Piccolo S, "The biology of YAP", TAZ: hippo signaling and beyond, 2014, pp.94, 1287~1312
  14. Harvey KF, "Thomas, The Hippo pathway and human cancer", Nat Rev Cancer, 13, pp.246~257 (2013)[DOI]
  15. Yu FX, "Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer", Cell, 163, pp.811~828 (2015)[DOI]
  16. Piccolo S, "Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis", Clin Cancer Res, 19, pp.4925~4930 (2013)[DOI]
  17. Keren-Paz A, "YAP and the drug resistance highway", Nat Genet, 47, pp.193~194 (2015)[DOI]
  18. Jiao S, "A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer", Cancer Cell, 25, pp.166~180 (2014)[DOI]
  19. Steinhardt AA, "Expression of Yes-associated protein in common solid tumors", Hum Pathol, 39, pp.1582~1589 (2008)[DOI]
  20. Wang Y, "Clinical and prognostic significance of Yes-associated protein in colorectal cancer", Tumour Biol, 34, pp.2169~2174 (2013)[DOI]
  21. Camargo FD, "YAP1 increases organ size and expands undifferentiated progenitor cells", Curr Biol, 17, pp.2054~2060 (2007)[DOI]
  22. Chan EH, "The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1", Oncogene, 24, pp.2076~2086 (2005)[DOI]
  23. Hao Y, "Tumor suppressor LATS1 is a negative regulator of oncogene YAP", J Biol Chem, 283, pp.5496~5509 (2008)[DOI]
  24. Zhao B, "TEAD mediates YAP-dependent gene induction and growth control", Genes Dev, 22, pp.1962~1971 (2008)[DOI]
  25. Flaherty KT, "From genes to drugs: targeted strategies for melanoma", Nat Rev Cancer, 12, pp.349~361 (2012)[DOI]
  26. Eggermont AM, "Melanoma in 2011: a new paradigm tumor for drug development", Nat Rev Clin Oncol, 9, pp.74~76 (2012)[DOI]
  27. Jones PS, "New regulatory framework for cancer drug development", Drug Discov Today, 17, pp.227~231 (2012)[DOI]
  28. Mullard A, "The Roadmap Epigenomics Project opens new drug development avenues", Nat Rev Drug Discov, 14, pp.223~225 (2015)[DOI]
  29. Vukicevic S, "Current Challenges and Hurdles in New Drug Development", Clin Ther, 38, pp.e3~ (2016)
  30. De Angelis ML, "How to Assess Drug Resistance in Cancer Stem Cells", Methods Mol Biol, 1692, pp.107~115 (2018)
  31. Emery CM, "MEK1 mutations confer resistance to MEK and B-RAF inhibition", Proc Natl Acad Sci U S A, 106, pp.20411~20416 (2009)[DOI]
  32. Guang MHZ, "Overcoming multiple myeloma drug resistance in the era of cancer 'omics'", Leuk Lymphoma, 59, pp.542~561 (2018)[DOI]
  33. Norouzi-Barough L, "Molecular Mechanisms of Drug Resistance in Ovarian Cancer", J Cell Physiol (2017)
  34. Siegfried Z, "The role of alternative splicing in cancer drug resistance", Curr Opin Genet Dev, 48, pp.16~21 (2017)
  35. Mansoori B, "The Different Mechanisms of Cancer Drug Resistance: A Brief Review", Adv Pharm Bull, 7, pp.339~348 (2017)[DOI]
  36. Lin CH, "Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors", Mol Biol Cell, 26, pp.3946~3953 (2015)[DOI]
  37. Lin L, "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies", Nat Genet, 47, pp.250~256 (2015)[DOI]
  38. Guo L, "YAP", TAZ for cancer therapy: opportunities and challenges (review), 2015, pp.46, 1444~1452
  39. Moroishi T, "The emerging roles of YAP and TAZ in cancer", Nat Rev Cancer, 15, pp.73~79 (2015)[DOI]
  40. Ma Y, "Hippo-YAP signaling pathway: A new paradigm for cancer therapy", Int J Cancer, 137, pp.2275~2286 (2015)[DOI]
  41. Kim MH, "Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP", TAZ activation, 2016, pp.35, 462~478
  42. Hsu PC, "YAP promotes erlotinib resistance in human non-small cell lung cancer cells", Oncotarget, 7, pp.51922~51933 (2016)
  43. Zanconato F, "YAP", TAZ as therapeutic targets in cancer, 2016, pp.29, 26~33
  44. Andl T, "YAP and WWTR1: New targets for skin cancer treatment", Cancer Lett, 396, pp.30~41 (2017)[DOI]
  45. Kim MH, "Role of YAP", TAZ transcriptional regulators in resistance to anti-cancer therapies, 2017, pp.74, 1457~1474
  46. Sun PL, "Reply: YAP is a Key Factor to Improve the Management of Cancer Treatments", Ann Surg Oncol, 24, pp.644~645 (2017)[DOI]
  47. Zhang Y, "VGLL4 Selectively Represses YAP-Dependent Gene Induction and Tumorigenic Phenotypes in Breast Cancer", Sci Rep, 7, pp.6190~ (2017)[DOI]
  48. Ahmed AA, "YAP and the Hippo pathway in pediatric cancer", Mol Cell Oncol, 4, pp.e1295127~ (2017)[DOI]
  49. Avril T, "Proteostasis trumps YAP in colon cancer", Sci Signal, 8, pp.fs18~ (2015)[DOI]
  50. Cao L, "Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues", Hum Pathol, 68, pp.166~174 (2017)[DOI]
  51. Eibl G, "YAP, and obesity in pancreatic cancer: A signaling network with multiple loops", Semin Cancer Biol (2017)
  52. Feng J, "Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer", Onco Targets Ther, 9, pp.5371~5381 (2016)[DOI]
  53. Kim HM, "Expression of Yes-associated protein (YAP) in metastatic breast cancer", Int J Clin Exp Pathol, 8, pp.11248~11257 (2015)
  54. Maugeri-Sacca M, "The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications", Expert Rev Mol Med, 17, pp.e14~ (2015)[DOI]
  55. Zanconato F, "YAP", TAZ at the Roots of Cancer, 2016, pp.29, 783~803
  56. Zhou GX, "Effects of the hippo signaling pathway in human gastric cancer", Asian Pac J Cancer Prev, 14, pp.5199~5205 (2013)[DOI]
  57. Formisano L, "From biology to therapy: Improvements of therapeutic options in Lung cancer", Anticancer Agents Med Chem (2017)
  58. Lemjabbar-Alaoui H, "Lung cancer: Biology and treatment options", Biochim Biophys Acta, 1856, pp.189~210 (2015)
  59. Suda K, "Molecular Biology for Surgical Treatment of Lung Cancer", Kyobu Geka, 70, pp.4~8 (2017)
  60. Lee BS, "Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma", Biochem Biophys Res Commun, 491, pp.493~499 (2017)[DOI]
  61. Lee JE, "Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance", Biochem Biophys Res Commun, 474, pp.154~160 (2016)[DOI]
  62. Karachaliou N, "76P An innovative co-targeting of signal transducer and activator of transcription 3 (STAT3) and Src-YAP pathways in EGFR mutant non-small cell lung cancer (NSCLC)", J Thorac Oncol, 11, pp.87~88 (2016)
  63. Wang H, "Tankyrase Inhibitor Sensitizes Lung Cancer Cells to Endothelial Growth Factor Receptor (EGFR) Inhibition via Stabilizing Angiomotins and Inhibiting YAP Signaling", J Biol Chem, 291, pp.15256~15266 (2016)[DOI]
  64. Parsa Y, "A Review of the Clinical Implications of Breast Cancer Biology", Electron Physician, 8, pp.2416~2424 (2016)[DOI]
  65. Chan SW, "A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells", Cancer Res, 68, pp.2592~2598 (2008)[DOI]
  66. Cordenonsi M, "The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells", Cell, 147, pp.759~772 (2011)[DOI]
  67. Diaz-Martin J, "Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer", Endocr Relat Cancer, 22, pp.443~454 (2015)[DOI]
  68. Li YW, "Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis", Cell Cycle, 14, pp.146~156 (2015)[DOI]
  69. Bartucci M, "TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells", Oncogene, 34, pp.681~690 (2015)[DOI]
  70. Yuan M, "Yes-associated protein (YAP) functions as a tumor suppressor in breast", Cell Death Differ, 15, pp.1752~1759 (2008)[DOI]
  71. Kim SK, "Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer", Int J Clin Exp Pathol, 7, pp.3224~3234 (2014)
  72. Jaramillo-Rodriguez Y, "YAP expression in normal and neoplastic breast tissue: an immunohistochemical study", Arch Med Res, 45, pp.223~228 (2014)[DOI]
  73. Kagawa Y, "Molecular biology of colon cancer", Nihon Rinsho, 69, pp.67~71 (2011)
  74. Zhang L, "Role of apoptosis in colon cancer biology, therapy, and prevention", Curr Colorectal Cancer Rep, 9 (2013)
  75. Kim HB, "Prostaglandin E2 Activates YAP and a Positive-Signaling Loop to Promote Colon Regeneration After Colitis but Also Carcinogenesis in Mice", Gastroenterology, 152, pp.616~630 (2017)[DOI]
  76. Ling HH, "Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer", Exp Cell Res, 350, pp.218~225 (2017)[DOI]
  77. Lee KW, "Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients", Clin Cancer Res, 21, pp.357~364 (2015)[DOI]
  78. Jerhammar F, "YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer", Oral Oncol, 50, pp.832~839 (2014)[DOI]
  79. Hernanda PY, "Multipotent mesenchymal stromal cells in liver cancer: implications for tumor biology and therapy", Biochim Biophys Acta, 1846, pp.439~445 (2014)
  80. Kudo M, "Targeted therapy for liver cancer: updated review in 2012", Curr Cancer Drug Targets, 12, pp.1062~1072 (2012)
  81. Oishi N, "Molecular biology of liver cancer stem cells", Liver Cancer, 3, pp.71~84 (2014)[DOI]
  82. 김영은, "Deubiquitinase YOD1: the potent activator of YAP in hepatomegaly and liver cancer", BMB Reports, 50(6), pp.281~282 (2017), 생화학분자생물학회
  83. Liu AM, "Targeting YAP and Hippo signaling pathway in liver cancer", Expert Opin Ther Targets, 14, pp.855~868 (2010)[DOI]
  84. Liu AM, "An update on targeting Hippo-YAP signaling in liver cancer", Expert Opin Ther Targets, 16, pp.243~247 (2012)[DOI]
  85. Liu-Chittenden Y, "Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP", Genes Dev, 26, pp.1300~1305 (2012)[DOI]
  86. Yimlamai D, "Emerging evidence on the role of the Hippo", YAP pathway in liver physiology and cancer, 2015, pp.63, 1491~1501
  87. Han SX, "Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma", J Immunol Res, 2014, pp.261365~ (2014)
  88. Cervantes A, "Molecular biology of gastric cancer", Clin Transl Oncol, 9, pp.208~215 (2007)[DOI]
  89. Dreznik A, "Gastric cancer: biology and clinical manifestations in Israel", J Surg Oncol, 105, pp.316~322 (2012)[DOI]
  90. El-Rifai W, "Molecular biology of gastric cancer", Semin Radiat Oncol, 12, pp.128~140 (2002)[DOI]
  91. Cai J, "The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program", Genes Dev, 24, pp.2383~2388 (2010)[DOI]
  92. Zhou D, "Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance", Proc Natl Acad Sci U S A, 108, pp.E1312~E1320 (2011)[DOI]
  93. Kaan HYK, "Crystal structure of TAZ-TEAD complex reveals a distinct interaction mode from that of YAP-TEAD complex", Sci Rep, 7, pp.2035~ (2017)[DOI]
  94. Zhang Z, "Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP-TEAD Protein-Protein Interaction", ACS Med Chem Lett, 5, pp.993~998 (2014)[DOI]

관련 논문AI추천

Hepatic Hippo signaling inhibits development of hepatocellular carcinomaXiaohui Wang, Yingzi Yang, Yuchen Liu대한간학회 · Clinical and Molecular Hepatology2020 · 제26권 제4호The multifaceted role of YAP in the tumor microenvironment and its therapeutic implications in cancerKim Hyung-Sik, Nam Jeong-Seok생화학분자생물학회 · Experimental and Molecular Medicine2025 · 제57권 The role of extracellular biophysical cues in modulating the Hippo-YAP pathway모정순생화학분자생물학회 · BMB Reports2017 · 제50권 제2호The history and regulatory mechanism of the Hippo pathway김완태, 조익훈생화학분자생물학회 · BMB Reports2018 · 제51권 제3호Cross-talk between Wnt/β-catenin and Hippo signaling pathways: a brief review김민성, 조익훈생화학분자생물학회 · BMB Reports2014 · 제47권 제10호Interacting network of Hippo, Wnt/β-catenin and Notch signaling represses liver tumor formation김완태, Sanjoy Kumar Khan, Yingzi Yang생화학분자생물학회 · BMB Reports2017 · 제50권 제1호

이 간행물의 다른 논문 (7건)

Hippo signaling: Special issue of BMB Reports in 2018조익훈pp. 105-105The history and regulatory mechanism of the Hippo pathway김완태, 조익훈pp. 106-118DNA binding partners of YAP/TAZ김민규, 장주원, 배석철pp. 126-133Upstream paths for Hippo signaling in Drosophila organ development최광욱pp. 134-142Regulation of the Hippo signaling pathway by ubiquitin modification조익훈, 김영은pp. 143-150
원문 보기